Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015)

Ocugen's (OCGN) quarterly Long-Term Deferred Tax came in at $1.1 million in Q3 2015, up 0.86% on a QoQ basis from $1.0 million in Q2 2015.

Analysis

Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015) Analysis & Trends

Ocugen (OCGN) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.1 million in Q3 2015.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $1.1 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $1.1 million (changed N/A YoY) and the FY2014 annual result came in at $651000.0, changed N/A from the prior year.
Long-Term Deferred Tax climbed to $1.1 million in Q3 2015, from $1.0 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $1.1 million in Q3 2015 to a low of $651000.0 in Q4 2014.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Ocugen	458.91 Mn	358.81 Mn	-

Historic Data

Download Data